Light Chain Bioscience (LCB), a brand of Novimmune SA, is a drug discovery and development company located in Geneva, Switzerland. To date, Novimmune has generated seven therapeutic antibodies, successfully bringing one to approval for an orphan indication in children. The focus is now on the generation of fully human bispecific antibodies using a proprietary technology platform.
Helping the body to fight cancer
Multispecific yet truly natural antibodies
Our biotechnology company researches, develops, and manufactures bispecific antibodies for the treatment of malignant tumors. We redirect the patient´s own immune cells, especially macrophages, T-cells and natural killer cells, to attack cancer cells – helping the body to fight cancer
